Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 19.75p 19.50p 21.00p - - - 0.00 07:31:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.5 -12.1 -2.3 - 117.21

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Share Charts

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
10/11/201607:15Allergy Therapeutics - AGY -3,178.00
14/7/201620:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1.00
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26.00
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79.00

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08/12/2016 15:59:1719.5311,1132,169.81O
08/12/2016 15:23:1619.895,000994.50O
08/12/2016 15:22:1319.895,000994.50O
08/12/2016 12:29:3019.5935,8047,014.08O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

DateSubject
08/12/2016
08:20
Allergy Therapeutics Daily Update: Allergy Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 19.75p.
Allergy Therapeutics has a 4 week average price of 20.89p and a 12 week average price of 21.23p.
The 1 year high share price is 32.50p while the 1 year low share price is currently 0p.
There are currently 593,444,020 shares in issue and the average daily traded volume is 95,632 shares. The market capitalisation of Allergy Therapeutics is £117,205,193.95.
15/10/2016
10:38
lordshaw: iii article: In a week when the FTSE 100 finally made an all-time high there were surprisingly few big winners among either the large or mid-caps. A three-day losing streak for the blue-chip index clearly took some froth out of the market, which is why we cast our net a bit wider in search of our Share of the week. In fact, we headed all the way to AIM where an old favourite was causing a stir. We last covered Allergy Therapeutics (AGY) in September following full-year results. Revenue had risen fast, but heavy R&D spend meant big full-year losses and a possible delay to profitability. However, one analyst reckoned an enterprise value (EV)/sales ratio of just 1.6 times made the shares "very cheap", with peers trading on a ratio of three times. It's why Paul Cuddon at Numis slapped a 37p price target on the shares. That article - Allergy Therapeutics tipped to bounce back - was nearly three weeks ago, and things have really taken off since. In the days following our write-up, directors opened their wallets, snapping up 280,000 Allergy shares at 17.75-19.25p. Chief executive Manuel Llobet kicked things off, buying 100,000 at 18p. Finance director Nicolas Wykeman picked up 150,000 at 17.75p, before chairman Peter Jensen bagged 30,000 at 19.25p. This Friday, the share price peaked at 25p, up 45% since the results. It's also a five-month high, and just a penny from the 50% Fibonacci retracement of the decline from the October 2015 best at 35p. Clearly, the market also liked news Monday that Allergy would present data at the World Vaccine Congress, demonstrating how its adjuvants can make "significant improvements" in the effectiveness of malaria vaccines. Data also implies "highly significant" potential for this novel adjuvant system in infectious disease applications using Allergy's Bencard Adjuvant Systems (BAS) technology, we're told. Panmure Gordon has been a fan for ages, and remains a buyer, believing Allergy could be worth 53p a share in time. The broker's sum-of-the-parts valuation is based on enterprise value/sales analysis of specialty pharma and allergy peers for calendar year 2017, estimated balance sheet cash and net present value of its Pollinex Quattro hay fever treatment.
29/9/2016
17:14
jimmyloser: From elsewhere on the web Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon by: Amilia Stone 26th September 2016 Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP. Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World.
09/5/2016
15:17
audigger: Thanks for posting. I guess at some point the company themselves need to engage with a strategy to push their prospects with investors and to energise the share price to catch-with its peers. Right now though they are quite rightly focuses on the clinical trials.
21/4/2016
16:06
thomasthetank1: Read Panmure Gordon & Co's note on ALLERGY THERAPEUTICS, out this morning, by visiting hxxps://www.research-tree.com/company/GB00B02LCQ05 "We added Allergy Therapeutics to the Conviction List in Q315 and the strength of the share price performance during 2H15 saw the stock as one of our top performers. Interim results in March confirmed strong double digit constant currency revenue growth against a flat market backdrop. We expect catalysts in 2016 to include key clinical updates and continued commercial traction underpinning market share gains, so with the share price presently in the mid- 20p range we repeat..."
09/3/2016
08:57
qackers: http://www.directorstalk.com/bullish-gap-up-for-allergy-therapeutics-plc-after-better-fundamentals/ Bullish Gap Up for Allergy Therapeutics plc After Better FundamentalsDavid Hannula | March 9, 2016 The stock of Allergy Therapeutics plc (LON:AGY) gapped up by GBX 0.25 today and has GBX 37.05 target or 34.00% above today’s GBX 27.65 share price. The 6 months technical chart setup indicates low risk for the GBX 162.86 million company. The gap was reported on Mar, 9 by Barchart.com. If the GBX 37.05 price target is reached, the company will be worth GBX 55.37M more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 1.47% or GBX 0.4 on March 8, hitting GBX 27.65. About 26,621 shares traded hands. Allergy Therapeutics plc (LON:AGY) has risen 3.29% since August 6, 2015 and is uptrending. It has outperformed by 8.95% the S&P500. Out of 3 analysts covering Allergy Therapeutics PLC (LON:AGY), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Allergy Therapeutics PLC was the topic in 13 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock on March 8 with “Buy” rating. Allergy Therapeutics Plc is a United Kingdom pharmaceutical company. The company has a market cap of 162.86 million GBP. The Firm focuses on the treatment and prevention of allergy with aluminum free products. It has 294.15 P/E ratio. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
22/2/2016
12:12
jimmyloser: Sir, Am I alone in scratching my head at the share price travails here? Do we have exposure to China? Does the weakened pound impact negatively? Are the various trials all behind schedule? Yours etc
13/10/2015
12:04
qackers: http://www.proactiveinvestors.co.uk/companies/news/116158/allergy-therapeutics-has-major-opportunity-in-us-says-stifel-116158.html Allergy Therapeutics has major opportunity in US, says Stifel 10:19 13 Oct 2015 Just for the grass vaccine allergy alone Stifel is predicting sales of US$400mln by 2023. Allergy Therapeutics has major opportunity in US, says Stifel The company has already invested over US$100mln developing its flagship Pollinex Quattro (PQ) product portfolio for the US market. Allergy Therapeutics (LON:AGY) has a good business in Europe, but it is the US opportunity that can transform the hay fever vaccine group according to broker Stifel. The broker notes the company has already invested over US$100mln developing its flagship Pollinex Quattro (PQ) product portfolio for the US market. After initial delays, a first US product launch is now slated for 2019 and just for the grass vaccine allergy alone Stifel is predicting sales of US$400mln by 2023. With around 1m allergy sufferers in the US receiving allergy immunotherapy (AIT) for their grass allergies each year and an annual treatment cost of around $2,000 per person, the grass AIT market is potentially worth $2bn in the US. Stifel sees Pollinex Quattro Grass achieving a 20% market share. Ragweed and Trees vaccines are expected to follow and from its full Pollinex Quattro portfolio Allergy believes it can generate revenues of between US$800-1,000. Stifel has started its coverage with a target price of 79p, compared to a current share price of 27p, or about 200% upside. Buy is the broker’s investment view. “With multiple catalysts expected over the next 12-24 months, we expect the shares to outperform.” Share Philip Whiterow
05/3/2014
07:48
jimmyloser: I have thought of that and have read the prospectus and cannot see why they would at this stage. Having read that prospectus, I really am baffled as to why AGY share price is in pennies NO RAMP INTENDED. There have been encouraging signs that the board are now starting to market the company better. I repeat myself again. THIS MONTH IS HUGE FOR ALL INVOLVED HERE We have results on the 24th and 'hopefully' some solid USA news along with the Circassia floatation. I am shamefaced but will openly admit that when I bought into Allergy in January that I didn't realise that I had a potentially massive tiger by the tail. Really is the best money I have invested.
20/2/2014
13:59
audigger: Looks like the demand for these is still high and the availability limited hence another leg-up. Long may it continue. Clealry there is a linear relationship between the AGY share price and the miles that Cube's dog gets walked........
10/2/2014
18:06
cube boss: Apart from an old piece of news in a glossy magazine, we haven't had any news and we are climbing very nice! I think we are rising at a fast rate because the news that is due, it's going to be company changing! it's going to put us in a different league. Remember the Multi-billion market in the US alone, our vaccine will change the way people live in the US. It's like an oil company who have just spudded and are expecting multi million barrels in a couple of months if all goes well. The only difference is, Allergy Therapeutics "CAN'T" have a duster!! we know this works and will change peoples life's. AGY share price has been suppressed for the last 7 years since the FDA put the clinical hold on, now people are starting to wake up. So for these reasons, I can't help being a BIG Believer..:0)))
Allergy Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161209 07:49:14